Literature DB >> 19037836

Therapeutic prostate cancer vaccines: a review of the latest developments.

Mahsa Mohebtash1, Ravi A Madan, James L Gulley, Philip M Arlen.   

Abstract

Therapeutic cancer vaccines are well-tolerated immunotherapy modalities designed to activate the immune system to kill cancer cells without a significant effect on healthy cells. An improved understanding of tumor immunology has led to improved strategies in vaccine development, which in turn have resulted in improved outcomes. This review discusses different types of cancer vaccines, with a focus on prostate cancer vaccines because of the high prevalence of prostate cancer and the wide variety of approaches used in prostate cancer immunotherapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19037836      PMCID： PMC3487159     

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  20 in total

1.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Authors:  E J Small; P Fratesi; D M Reese; G Strang; R Laus; M V Peshwa; F H Valone
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

Review 2.  Quantitating therapeutically relevant T-cell responses to cancer vaccines.

Authors:  A C Hobeika; T M Clay; P J Mosca; H K Lyerly; M A Morse
Journal:  Crit Rev Immunol       Date:  2001       Impact factor: 2.214

3.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.

Authors:  Mary L Disis; Theodore A Gooley; Kristine Rinn; Donna Davis; Michael Piepkorn; Martin A Cheever; Keith L Knutson; Kathy Schiffman
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas.

Authors:  J M Timmerman; C B Caspar; S L Lambert; A D Syrengelas; R Levy
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

5.  Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.

Authors:  Ravi A Madan; James L Gulley; Jeffrey Schlom; Seth M Steinberg; David J Liewehr; William L Dahut; Philip M Arlen
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

6.  Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.

Authors:  David Avigan; Baldev Vasir; Jianlin Gong; Virginia Borges; Zekui Wu; Lynne Uhl; Michael Atkins; James Mier; David McDermott; Therese Smith; Nancy Giallambardo; Carolyn Stone; Kim Schadt; Jennifer Dolgoff; Jean-Claude Tetreault; Marisa Villarroel; Donald Kufe
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

7.  Clinical safety of a viral vector based prostate cancer vaccine strategy.

Authors:  Philip M Arlen; Lisa Skarupa; Mary Pazdur; Mahesh Seetharam; Kwong Y Tsang; Douglas W Grosenbach; Jarett Feldman; Diane J Poole; Mary Litzinger; Seth M Steinberg; Elizabeth Jones; Clara Chen; Jennifer Marte; Howard Parnes; John Wright; William Dahut; Jeffrey Schlom; James L Gulley
Journal:  J Urol       Date:  2007-08-16       Impact factor: 7.450

8.  Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.

Authors:  Alexander Stojadinovic; Elizabeth A Mittendorf; Jarrod P Holmes; Asna Amin; Matthew T Hueman; Sathibalan Ponniah; George E Peoples
Journal:  Ann Surg Oncol       Date:  2007-09-29       Impact factor: 5.344

9.  Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

Authors:  Howard L Kaufman; Wei Wang; Judith Manola; Robert S DiPaola; Yoo-Joung Ko; Christopher Sweeney; Theresa L Whiteside; Jeffrey Schlom; George Wilding; Louis M Weiner
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

10.  Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.

Authors:  Eric J Small; Natalie Sacks; John Nemunaitis; Walter J Urba; Eugene Dula; Arthur S Centeno; William G Nelson; Dale Ando; Catherine Howard; Flavia Borellini; Minh Nguyen; Kristen Hege; Jonathan W Simons
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531
View more
  2 in total

1.  HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy.

Authors:  Bently Patrick Doonan; Azizul Haque
Journal:  Open Cancer Immunol J       Date:  2010-01-01

2.  Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Authors:  Bently P Doonan; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2015-08-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.